RBC Capital Markets noted disappointing trial results for Compass Pathways, whose drug faces competition from Johnson & Johnson's Spravato.
1 report, 0 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
RBC Capital Markets noted disappointing trial results for Compass Pathways, whose drug faces competition from Johnson & Johnson's Spravato.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
RBC Capital Markets
global investment bank
- Financial institutions like RBC and Macquarie maintained 'outperform' ratings amid dashed hopes for a Strait of Hormuz reopening.
- Kratos Defense & Security Solutions filed a shelf registration statement with the SEC, with Robert W. Baird & Co. and RBC Capital Markets acting as joint book-running managers.
-
Compass Pathways
mental health care company
Nothing else this week.
Related events
- Telix Pharmaceutical is seeking US FDA approval for a new drug agent, accompanied by analyst commentary on its market performance.
- RBC Capital Markets advised LCN Capital Partners in a recent deal.
- Johnson & Johnson and Compass Pathways are both involved in the advanced psychedelic therapy market, currently submitting applications for COMP360 approval.
Coverage
Newest first; wire copies grouped- Unknown outlet